AnaptysBio (ANAB) Posts Earnings Results, Beats Expectations By $0.05 EPS

Share on StockTwits

AnaptysBio (NASDAQ:ANAB) announced its earnings results on Thursday. The biotechnology company reported ($0.66) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.71) by $0.05, Fidelity Earnings reports. The business had revenue of $5.00 million during the quarter.

AnaptysBio stock opened at $72.33 on Friday. The stock has a market capitalization of $2.07 billion, a P/E ratio of -47.59 and a beta of 3.47. AnaptysBio has a 12-month low of $65.93 and a 12-month high of $134.00. The company has a current ratio of 16.19, a quick ratio of 16.19 and a debt-to-equity ratio of 0.01.

A number of analysts have recently weighed in on ANAB shares. Credit Suisse Group set a $147.00 target price on AnaptysBio and gave the company a “buy” rating in a research note on Thursday, September 27th. Cantor Fitzgerald set a $124.00 target price on AnaptysBio and gave the company a “buy” rating in a research note on Saturday, September 22nd. JMP Securities lowered their target price on AnaptysBio from $180.00 to $153.00 and set a “buy” rating for the company in a research note on Wednesday, August 15th. Stifel Nicolaus set a $127.00 target price on AnaptysBio and gave the company a “buy” rating in a research note on Friday, September 14th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $121.00 target price on shares of AnaptysBio in a research note on Tuesday, August 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $130.50.

WARNING: This report was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3928923/anaptysbio-anab-posts-earnings-results-beats-expectations-by-0-05-eps.html.

About AnaptysBio

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Read More: Discount Rate

Earnings History for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Comparing Matthews International  & IBC Advanced Alloys
Comparing Matthews International & IBC Advanced Alloys
Critical Review: Lightwave Logic  versus KushCo
Critical Review: Lightwave Logic versus KushCo
Rcoin  Price Hits $0.0001 on Top Exchanges
Rcoin Price Hits $0.0001 on Top Exchanges
Marijuanacoin  Price Tops $0.0105
Marijuanacoin Price Tops $0.0105
BIO-key International  Releases  Earnings Results
BIO-key International Releases Earnings Results
Bezant Price Down 39.7% Over Last 7 Days
Bezant Price Down 39.7% Over Last 7 Days


Leave a Reply

© 2006-2018 Ticker Report